Sydney Oesch 2/18/25 Sydney Oesch 2/18/25

Chemotherapy: IO

In this episode, we’ll discuss mechanisms of action, indications for use, and toxicities associated with immunotherapies (Immune Related Adverse Events, IRAE) in gynecologic cancers.

Sydney Oesch 10/1/24 Sydney Oesch 10/1/24

Chemotherapy: HIPEC and IPC

In this episode, we discuss Intraperitoneal chemotherapy (IPC) and Heated Intraperitoneal Chemotherapy (HIPEC), including clinical trials of these agents in ovarian cancer and practical tips for utilizing HIPEC in clinical practice.

Sydney Oesch 9/17/24 Sydney Oesch 9/17/24

Chemotherapy: PARP-I, Bevacizumab, and Ovarian Cytotoxics

Chemotherapy: PARP-I, Bev, Ovarian Cytotoxics

In this episode, we discuss antineoplastic agents for ovarian cancer. We discuss PARP-inhibitors, homologous recombination deficiency, bevacizumab, as well as new cytotoxic chemotherapy used in the treatment of ovarian cancers.

Sydney Oesch 5/28/24 Sydney Oesch 5/28/24

Uterine Cytotoxic Therapies

In our second chemotherapy episode, we will explore some commonly used cytotoxic therapies in gynecologic oncology. Specifically, we will discuss in detail mechanisms of action, side effects, and other considerations of individual cytotoxic agents used in the treatment of uterine cancers.

Sydney Oesch 5/14/24 Sydney Oesch 5/14/24

Chemotherapy principles

In our first chemotherapy episode, we will explore the fundamental principles of tumor growth and chemotherapy. We will discuss tumor growth kinetics, theory behind combination chemotherapy and dosing cycles, pharmacokinetics, how to calculate doses for certain agents, and how to determine whether a therapy regimen is effective for a patient.